ObjectivesTo evaluate the feasibility and safety of the new REVO-I robotic platform by performing Fallopian tube transection and anastomosis in live porcine models.
Subjects and MethodsA prospective chronic animal study was carried out in four crossbred female pigs. The primary outcome was assessment of the pigs' 2-week survival. The secondary outcomes were measurements of intra-operative variables and the complications or difficulties arising when using the REVO-I.
ResultsFallopian tube anastomosis was successfully performed in four porcine models. The mean (range) operating time was 66 (46-104 min), docking time 22.25 (14-53) min and console time 18 (13-20) min. The REVO-I robotic system functioned appropriately, with no technical problems or difficulties noted during the procedures. Both the surgeon and the bedside assistants reported ease of use and better performance with subsequent procedures. All pigs were alive 2 weeks after surgery, with no peri-operative complications related to the use of the robot.
ConclusionsThis preclinical chronic porcine study showed that the REVO-I robotic surgical system is a feasible and safe robotic instrument that can be used by surgeons to perform skillful robotic procedures in porcine models. Our next objective will be to demonstrate its safety in humans.
We present a 61-year-old man who was diagnosed with synchronous prostate cancer and suspicious renal cell carcinoma of the right kidney, treated with combined Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) and robot-assisted partial nephrectomy (RAPN). The combined approach using RS-RARP and RAPN is technically feasible and safe surgical option for treatment of concomitant prostate cancer and suspicious renal cell carcinoma.
significantly more of these urinary infections (HR 1.4, 95% CI 1.1-1.7, p<0.01). Reconstructive bladder surgery/urinary diversion was carried out on 2.4% of patients, and was significantly more likely among patients with cervical injuries (HR 2.36, 95% CI 1.28-4.37, p<0.01. There were 107 patients with renal dysfunction, which was new since the TSCI for 79% (84/107). Lesion level was not significantly associated with renal dysfunction (HR 1.00, 95% CI 0.64-1.57, p¼1.00). The rate ratio for urinary tract infections requiring a hospital visit (14.91, 95% CI 12.79-17.37), bladder reconstruction/diversion (6.48, 95% CI 3.07-13.68), and renal failure (1.79, 95% CI 1.31-2.45) was significantly increased among TSCI patients compared to matched controls. CONCLUSIONS: Urologic disease is still an important source of morbidity for contemporary TSCI patients. Urinary tract infections are common. Reconstructive bladder surgery or diversion is rarely performed. Chronic renal failure is more common among TSCI patients, however the relative risk of this was modest.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.